Status:
COMPLETED
Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients
Lead Sponsor:
University of Shizuoka
Collaborating Sponsors:
Maruyama Memorial General Hospital
Hamamatsu University
Conditions:
Chronic Renal Failure
Hemodialysis
Eligibility:
All Genders
Up to 70 years
Brief Summary
Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) have recently been recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these sub...
Detailed Description
Objective- Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) have recently been recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each o...
Eligibility Criteria
Inclusion
- The study inclusion criteria were those patients who had been receiving hemodialysis therapy for more than 6 months, were in a stable condition and were under 70 years old.
Exclusion
- Any patients showing signs of heart failure or a history of such apparent cardiovascular diseases as myocardial infarction, cardiac valve diseases and stroke were excluded.
Key Trial Info
Start Date :
April 1 2000
Trial Type :
OBSERVATIONAL
End Date :
March 1 2005
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00161369
Start Date
April 1 2000
End Date
March 1 2005
Last Update
October 21 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Shizuoka
Shizuoka, Shizuoka, Japan, 422-8526